CERT · Certara, Inc.

Current Thesis

Certara’s remaining recovery case depends on the next quarterly report showing realized cost savings while preserving annual guidance, after the 2026-09-11 close of $7.55 invalidated the prior price-supported thesis. The 2026-08-30 dossier specified a daily close below $7.90; that condition has occurred. The earlier recovery thesis therefore failed its published test.

The operating proposition remains management’s 2026-08-04 plan: approximately $13 million of annual run-rate savings alongside reaffirmed fiscal 2026 revenue guidance of $367–382 million and adjusted diluted earnings per share of $0.31–0.36. These are management expectations, not measured savings. The narrower, prospective case requires evidence of realized savings and unchanged annual guidance at the next report; a daily close below $6.87, the reported 2026-08-04 premarket low, would invalidate that remaining case.

As a price-supported recovery, the narrative is dead — the 2026-09-11 close breached the condition published on 2026-08-30. This classification describes the failed market structure; the August operating plan has not yet been settled by another quarterly result. Certara’s investor-relations page still lists 2026-08-04 as its latest earnings release when checked on 2026-09-13. Certara investor relations

Bullish and bearish views on Certara, Inc.

The model's bull view on Certara, Inc. (CERT), in brief: Software demand retained some growth. Certara’s 2026-08-04 release reported second-quarter software revenue of $48.8 million, up 4% year over year, and software bookings of $50.7 million, up 9%. These measured increases support the remaining operating case; declining software… The bear view: The published price test failed. The adjusted 2026-09-11 close of $7.55 was below the $7.90 invalidation threshold in the 2026-08-30 dossier. The earlier note’s description of an intact recovery no longer fits that observation. Services weakened alongside profitability. The… Both cases follow in full.

Bull Case

• Software demand retained some growth. Certara’s 2026-08-04 release reported second-quarter software revenue of $48.8 million, up 4% year over year, and software bookings of $50.7 million, up 9%. These measured increases support the remaining operating case; declining software bookings at the next report would contradict its demand component.
• Cost reductions have defined scope. The 2026-08-04 release described a workforce reduction of approximately 5% and approximately $13 million of expected annual run-rate savings, including stranded divestiture costs. Failure to report realized savings at the next quarterly update would leave the central mechanism unconfirmed.

Bear Case

• The published price test failed. The adjusted 2026-09-11 close of $7.55 was below the $7.90 invalidation threshold in the 2026-08-30 dossier. The earlier note’s description of an intact recovery no longer fits that observation.
• Services weakened alongside profitability. The 2026-08-04 release reported second-quarter services revenue of $44.5 million, down 3% year over year, and services bookings of $47.6 million, down 6%. further services contraction would challenge the proposition that cost reductions can stabilize earnings.
• Officer sale intent is disclosed. Leif E. The filing establishes proposed supply, not completed execution or a judgment about subsequent results. Pedersen Form 144

Setup & Price Structure

The supplied adjusted series records a 2026-09-11 close of $7.55 and a three-month price increase of 45.2%. Its 14-period relative strength index was 31.7 on that date. The positive trailing price change does not reverse the observed breach of $7.90. No moving-average value or complete intervening close series is supplied, so a rising-average support claim or an exact first-breach date cannot be established here.

The $6.87 reference is the 2026-08-04 premarket low recorded in the earlier public dossier. It is an intraday historical reference, not demonstrated closing support. Using it for the remaining operating-recovery case does not erase the earlier $7.90 failure.

Positioning evidence remains limited. Stock Analysis displayed eight hold ratings and four strong-buy ratings in its August 2026 distribution; its page identifies 2026-08-05 as the last target update. That measures analyst opinion, not investor flows. The September officer notice alone is too small a sample to establish broad distribution. Analyst distribution

Catalyst Calendar (next 30 days)

• 2026-09-21 — Certara Biotech Forum. The company lists a workshop on developing investor-ready strategies at the Cambridge Innovation Center. Its published description contains no scheduled financial-results update, so the event is not a dated resolution of the savings case. Company events
• ~2026-11-11, estimated — Third-quarter results. Outside the next 30 days, Finanzennet lists this estimated reporting date; company confirmation is absent from the investor-relations events reviewed on 2026-09-13. The earlier dossier’s estimated 2026-11-03 date is not confirmed. Results would test realized savings and whether management retains the annual revenue and earnings ranges. Third-party calendar, Company events

What Would Change Our Mind

Loss of the August premarket reference would end the remaining recovery case: a daily close below $6.87 is the prospective price condition. Separately, annual revenue guidance below $367 million or adjusted diluted earnings guidance below $0.31 per share would contradict the operating proposition reaffirmed on 2026-08-04. These conditions concern the remaining case; the previous $7.90 condition has already been met.

Evidence of realized cost savings alongside retained annual guidance at the next quarterly report would satisfy the remaining operating case. A favorable statement without disclosed savings would leave it unresolved. The approximately $13 million announced on 2026-08-04 was an annual run-rate expectation, not a quarterly savings commitment.

Correlation Notes

Certara’s 2026-07-07 NVIDIA announcement supplies an artificial-intelligence connection, but the dated financial mechanism in this dossier is the company-specific cost program announced on 2026-08-04. The supplied evidence contains no comparative return series or measured sector correlation. This remains a single-name recovery case; the sample is insufficient to claim that semiconductor or biotechnology strength would repair its broken price structure. Certara announcement listing